+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Long-term celiprolol therapy lowers fasting plasma leptin levels. Celiprolol Multicenter Study Group

Long-term celiprolol therapy lowers fasting plasma leptin levels. Celiprolol Multicenter Study Group

Cardiovascular Drugs and Therapy 14(1): 67-75

The effects of celiprolol on fasting plasma leptin levels, glucose tolerance, and insulin sensitivity were studied in a randomized, investigator-masked, and parallel clinical trial. Modified oral glucose tolerance tests (OGTT) were performed during the previous antihypertensive monotherapy (beta- or Ca-blocker, or ACE inhibitor), and 6 and 12 months after randomization to celiprolol (200-400 mg daily) or to control group, where the therapy was kept unchanged. One hundred sixty-nine dyslipidemic and hypertensive nondiabetics with an age range of 42-65 years and an average body mass index of 28.4 kg/m2 completed the study according to the protocol. The mean circulating leptin level decreased from 7.5 to 6.6 ng/mL in men (p < 0.05) and from 23.0 to 19.7 ng/mL in women during the 12-month celiprolol treatment. The incremental glucose area under the curve (AUC) in the 2-hour OGTT decreased from 3.8 to 3.0 h* mmol/L (p < 0.01), and insulin AUC decreased from 134 to 99 h* mU/L (p < 0.01). The insulin sensitivity index increased by 22% (p < 0.01) and the serum triglyceride level decreased by 15% in the celiprolol group. Changes in serum cholesterol were clinically insignificant. In the control group, no significant change was seen in any measured variable. A decrease in leptin levels in the celiprolol group was associated with improved insulin sensitivity, while the weight of the moderately obese patients did not change. The clinical significance of a 14% decrease in fasting plasma leptin level remains to be elucidated. The results suggest amelioration of leptin resistance during long-term celiprolol therapy.

(PDF emailed within 1 workday: $29.90)

Accession: 046567976

Download citation: RISBibTeXText

PMID: 10755203

Related references

Long-term celiprolol therapy lowers fasting plasma leptin levels. Cardiovascular Drugs & Therapy 14(1): 67-75, 2000

The results of a celiprolol drug surveillance study in Spain. The Celiprolol Multicenter Group. Anales de Medicina Interna 6(12): 619-623, 1989

Liquid chromatographic determination of total celiprolol or (S)-celiprolol and (R)-celiprolol simultaneously in human plasma. Journal of Chromatography B Biomedical Applications 683(2): 231-236, 1996

Cardiac effects of racemic celiprolol dextro celiprolol and levo celiprolol. Medical Science Research 18(22): 885-886, 1990

Comparison of celiprolol and propranolol in stable angina pectoris. Celiprolol International Angina Study Group. American Journal of Cardiology 67(8): 665-670, 1991

Effect of long-term celiprolol therapy on haemostasis in essential hypertension. Journal of Human Hypertension 9(9): 773-776, 1995

Effect of long-term treatment with celiprolol on pulmonary function in a group of mild hypertensive asthmatics. Journal of International Medical Research 16 Suppl 1: 27a-33a, 1988

Pharmacological studies of celiprolol: II. Alpha 2-Adrenoceptor blocking effects of a cardioselective beta-blocker, celiprolol. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 95(4): 201-208, 1990

Effect of long-term fasting and a subsequent meal on mRNA abundances of hypothalamic appetite regulators, central and peripheral leptin expression and plasma leptin levels in rainbow trout. Peptides 86: 162-170, 2015

A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factors. American Heart Journal 116(5 Pt 2): 1416-1421, 1988

Effect of celiprolol and metoprolol on lipids, fibrinogen and airways function in hyperlipidaemic hypertensives: a randomised double-blind long-term parallel group trial. Journal of Human Hypertension 9(2): 123-129, 1995

Treatment of coronary heart disease with the beta-1-receptor blocker celiprolol in a long-term study over a 12-month period. Wiener Medizinische Wochenschrift 137(12): 278-286, 1987

Plasma levels and the antihypertensive effect of the preparation celiprolol. Vutreshni Bolesti 25(6): 62-66, 1986